Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.60 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.60 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.60 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.60 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.60 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2436534 | 0.93 | L3MBTL1 (0.65) | TNKSPARP15PARP14PARP10TNKS2 | |
| SCHEMBL13087758 | 0.92 | AKR1C3 (0.65) | TNKSPARP15PARP14PARP10TNKS2 | |
| SCHEMBL31657173 | 0.92 | AKR1C3 (0.70) | TNKSPARP15PARP14PARP10TNKS2 | |
| SCHEMBL521860 | 0.91 | AKR1C3 (0.68) | TNKSPARP15PARP14PARP10TNKS2 | |
| SCHEMBL14217726 | 0.90 | L3MBTL1 (0.56) | TNKSPARP15PARP14PARP10TNKS2 | |
| SCHEMBL12260934 | 0.89 | L3MBTL1 (0.55) | TNKSPARP15PARP14PARP10TNKS2 | |
| SCHEMBL5873911 | 0.89 | SMN1; SMN2 (0.58) | TNKSPARP15PARP14PARP10TNKS2 | |
| SCHEMBL27149873 | 0.89 | L3MBTL1 (0.55) | TNKSPARP15PARP14PARP10TNKS2 | |
| SCHEMBL11494980 | 0.89 | L3MBTL1 (0.55) | TNKSPARP15PARP14PARP10TNKS2 | |
| SCHEMBL8569015 | 0.87 | CA1 (0.55) | TNKSPARP15PARP14PARP10TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4516835-A1 | SEMI-AROMATIC POLYESTER, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Zhuhai Kingfa Biomaterial Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| US-20250043069-A1 | SEMI-AROMATIC POLYESTER, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JIANGSU KINGFA SCI & TECH. ADVANCED MATERIALS CO., LTD. (CN) | 2025-02-06 | — | — | US | disclosed |
| EP-4174105-B1 | SEMI-AROMATIC POLYESTER AND PREPARATION METHOD AND APPLICATION THEREOF | JIANGSU KINGFA SCI & TECH ADV MAT CO LTD (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4174105-A1 | SEMI-AROMATIC POLYESTER AND PREPARATION METHOD AND APPLICATION THEREOF | Jiangsu Kingfa Sci. & Tech. Advanced Materials Co., Ltd. (CN) | 2023-05-03 | — | — | EP | disclosed |
| CN-105392816-A | Heat resistant polyethylene terephthalate and a process for the preparation of the same | ESTER IND LTD | 2016-03-09 | — | — | CN | disclosed |
| EP-2414350-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-12 | — | — | EP | disclosed |
| US-8796466-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-05 | — | — | US | disclosed |
| WO-2012039717-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
| US-20110077280-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | TNKS 3874/4885PARP15 4303/4885PARP14 4332/4885 |
| US-20110077280-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | TNKS 3874/4885PARP15 4303/4885PARP14 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.